SynthesisBMC immunology2025
Prognostic value of monocyte chemoattractant protein-1 in sepsis: a systematic review and meta-analysis.
Synthesis in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMonocyte chemoattractant protein-1 (MCP-1) has been utilized as a prognostic indicator for sepsis patients; however, the findings have been inconsistent. This meta-analysis seeks to elucidate the prognostic significance of MCP-1 in individuals diagnosed with sepsis.
methodsWe systematically queried four databases (Web of Science, PubMed, EMBASE, Cochrane Library) to identify studies published from the establishment of the databases until January 2025. Hazard ratios (HRs) with 95% CIs were employed to evaluate the prognostic significance of MCP-1 in this patient population. In our study, the Newcastle-Ottawa Quality Assessment Scale was evaluated for quality assessment, and Funnel plot was used for publication offset.
resultsA total of 592 patients from eight studies were included in the evaluation. The findings revealed that MCP-1 levels were significantly elevated in non-survivors compared to those who survived [SMD = 0.54, 95% CI: 0.25-0.82, P = 0.0002]. Our study demonstrated that elevated levels of MCP-1 were significantly associated with an unfavorable prognosis in patients with sepsis, with a hazard ratio (HR) of 1.36 (95% confidence interval: 1.25-1.48; P < 0.00001) using a random-effects model. The funnel plot indicated no publication bias.
conclusionThis meta-analysis suggests that elevated levels of MCP-1 could serve as a valuable prognostic indicator in sepsis patients, however, this conclusion still requires validation through higher-quality studies with longer-term follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.